Literature DB >> 8509653

Fast immunopurification of small amounts of specific antibodies on peptides bound to ELISA plates.

K Brahimi1, J L Pérignon, M Bossus, H Gras, A Tartar, P Druilhe.   

Abstract

ELISA is widely used as a means to detect antibodies, but the potential of ELISA plates as an immunosorbent for the purification of specific antibodies does not seem to have been evaluated. In this study, ELISA plates coated with peptides representing short sequences of various antigens from Plasmodium falciparum, the etiologic agent of human malaria, have been successfully used as a means to purify small amounts of the corresponding antibodies. ELISA plates, identical to those used for antibody detection, also permitted the evaluation of various elution conditions for each pairing of peptide and serum; we tested four eluting buffers (0.2 M glycine, pH 2.5; 0.2 M lysine, pH 11.5; 3.0 M MgCl2, 0.075 M Hepes, 25% ethylene glycol, pH 7.1-7.2 and 4 M NH4SCN in 0.1 M NaH2PO4, pH 6.0) with four pairs of peptides and sera. The ELISA plates could also be used to estimate the affinity of the eluted antibodies by the technique of Pullen et al. (1986). The eluted antibodies were compared to those obtained by immunopurification on recombinant proteins adsorbed on nitrocellulose filters. In contrast to the latter, they were not contaminated by antibodies directed against the carrier moiety of the recombinant protein. When used in immunofluorescence assays with various stages of the parasite the antibodies immunopurified on peptides bound to ELISA plates were able to react with the native antigens in the parasite.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8509653     DOI: 10.1016/0022-1759(93)90408-y

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  7 in total

1.  Immunogenicity of four Plasmodium falciparum preerythrocytic antigens in Aotus lemurinus monkeys.

Authors:  B L Perlaza; M Arévalo-Herrera; K Brahimi; G Quintero; J C Palomino; H Gras-Masse; A Tartar; P Druilhe; S Herrera
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

2.  The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro.

Authors:  M Theisen; S Soe; C Oeuvray; A W Thomas; J Vuust; S Danielsen; S Jepsen; P Druilhe
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

3.  Toward the rational design of a malaria vaccine construct using the MSP3 family as an example: contribution of antigenicity studies in humans.

Authors:  Corine G Demanga; Lena-Juliette Daher; Eric Prieur; Catherine Blanc; Jean-Louis Pérignon; Hasnaa Bouharoun-Tayoun; Pierre Druilhe
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

4.  Viral protein VP4 is a target of human antibodies enhancing coxsackievirus B4- and B3-induced synthesis of alpha interferon.

Authors:  Wassim Chehadeh; Pierre-Emmanuel Lobert; Pierre Sauter; Anne Goffard; Bernadette Lucas; Jacques Weill; Marie-Christine Vantyghem; Gunnar Alm; Pascal Pigny; Didier Hober
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

5.  Plasmodium falciparum serine repeat protein, a new target of monocyte-dependent antibody-mediated parasite killing.

Authors:  Soe Soe; Subhash Singh; Daniel Camus; Toshihiro Horii; Pierre Druilhe
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

6.  Human antibodies against Plasmodium falciparum liver-stage antigen 3 cross-react with Plasmodium yoelii preerythrocytic-stage epitopes and inhibit sporozoite invasion in vitro and in vivo.

Authors:  K Brahimi; E Badell; J P Sauzet; L BenMohamed; P Daubersies; C Guérin-Marchand; G Snounou; P Druilhe
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

7.  Plasmodium falciparum merozoite surface protein 6 is a dimorphic antigen.

Authors:  J Andrew Pearce; Tony Triglia; Anthony N Hodder; David C Jackson; Alan F Cowman; Robin F Anders
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.